Light-Activated gel shows promise for rare skin cancer

NCT ID NCT06470451

Terminated Disease control Sponsor: Soligenix Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 14, 2026 · Updated 3 times

Summary

This Phase 3 trial tests a gel called HyBryte, which is activated by visible light, for treating cutaneous T-cell lymphoma (CTCL), a rare type of skin cancer. About 80 adults with early-stage CTCL will apply the gel or a placebo twice a week for 18 weeks, then receive light treatment. The goal is to see if the gel can significantly reduce the size and severity of skin lesions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HyBryte (hypericin sodium) gel plus visible light activation
What this could lead to: If successful, this could provide a new topical treatment option for early-stage cutaneous T-cell lymphoma, potentially reducing skin lesions without systemic side effects.
What could go wrong: This is a relatively small Phase 3 trial (80 participants), and the treatment may not work better than placebo. Skin sensitivity and local reactions are possible risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mycosis fungoides primary cutaneous T-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CTCL CTCL/ MYCOSIS FUNGOIDES CUTANEOUS T-CELL LYMPHOMA MYCOSIS FUNGOIDES

Contacts and locations

Locations

Accellacare (PMG)

Wilmington, North Carolina, 28411, United States
Austin Institute for Clinical Research

Pflugerville, Texas, 78660, United States
Columbia University Medical Center

New York, New York, 10032, United States
Dawes Fretzin Dermatology Group

Indianapolis, Indiana, 46256, United States
Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
Inova Schar Cancer Institute

Fairfax, Virginia, 22031, United States
MD Anderson

Houston, Texas, 77030, United States
Mayo Clinic

Scottsdale, Arizona, 85259, United States
Medical Dermatology Specialists

Phoenix, Arizona, 85006, United States
Northwestern University

Chicago, Illinois, 60611, United States
Penn State Health Hershey Medical Center

Hershey, Pennsylvania, 17033, United States
Rochester Skin Lymphoma Medical Group

Fairport, New York, 14450, United States
Therapeutics Clinical Research

San Diego, California, 92123, United States
University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, 15213, United States
University of South Florida

Tampa, Florida, 33612, United States
Vanderbilt University

Nashville, Tennessee, 37212, United States
Washington University

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.